For instance, rMMN nanomedicines loaded with miR-30a-5p upregulated miR-30a-5p levels both in vitro and in vivo, thereby suppressing the malignant phenotype of ocular melanoma by targeting the transcription factor E2F7.119. This evidence concerns the gene E2F7 and ocular melanoma.